Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 13/20 | 0.44 |
| ▸ | CHRM4 | P08173 | 13/20 | 0.44 |
| ▸ | CHRM5 | P08912 | 13/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 13/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 13/20 | 0.44 |
| ▸ | F2 | P00734 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17327535 | 0.98 | CHRM2 (0.42) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL642472 | 0.98 | CHRM2 (0.42) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL606217 | 0.92 | F2 (0.44) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL642427 | 0.92 | F2 (0.44) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL608859 | 0.92 | F2 (0.44) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL4721124 | 0.84 | SMN1; SMN2 (0.36) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL11882083 | 0.82 | CA12 (0.40) | CA12CA1CA2CA9 | |
| SCHEMBL7908918 | 0.82 | ACE (0.47) | F2 | |
| SCHEMBL12436085 | 0.82 | CHRM2 (0.45) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL6447711 | 0.82 | CA12 (0.42) | CA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8119673-B2 | Compounds 148 | ASTRAZENECA AB (SE) | 2012-02-21 | — | — | US | disclosed |
| CN-102131802-A | Heterocyclic carboxamides useful as thrombin inhibitors | ASTRAZENECA AB | 2011-07-20 | — | — | CN | disclosed |
| US-20110130432-A1 | Heterocyclic Carboxamides For Use As Thrombin Inhibitors | ASTRAZENECA AB (SE) | 2011-06-02 | — | — | US | disclosed |
| EP-2321301-A1 | NEW HETEROCYCLIC CARBOXAMIDES FOR USE AS THROMBIN INHIBITORS | AstraZeneca AB (SE) | 2011-05-18 | — | — | EP | disclosed |
| WO-2009157860-A1 | NEW HETEROCYCLIC CARBOXAMIDES FOR USE AS THROMBIN INHIBITORS | ASTRAZENECA AB (SE) | 2009-12-30 | — | — | WO | disclosed |
| US-20090318517-A1 | Novel Compounds 148 | ASTRAZENECA AB (SE) | 2009-12-24 | — | — | US | disclosed |
| US-20090012087-A1 | New Aza-Bicyclohexane Compounds Useful As Inhibitors Of Thrombin | ASTRAZENECA AB (SE) | 2009-01-08 | — | — | US | disclosed |
| WO-2009004383-A2 | AZA-BICYCLOHEXANE COMPOUNDS USEFUL AS ANTICOAGULANTS | ASTRAZENECA AB (SE) | 2009-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110130432-A1 | Heterocyclic Carboxamides For Use As Thrombin Inhibitors | TFPI, TFPI2, SPINT2 | CHRM2 4148/4885CHRM4 4669/4885CHRM5 4141/4885 |
| US-20090318517-A1 | Novel Compounds 148 | SERPINB1, SPINT2, TFPI | CHRM2 4183/4885CHRM4 4639/4885CHRM5 4419/4885 |
| US-20090012087-A1 | New Aza-Bicyclohexane Compounds Useful As Inhibitors Of Thrombin | TFPI, TFPI2, ADAMTS1 | CHRM2 4342/4885CHRM4 4843/4885CHRM5 4656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.